Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Elenagen||Elenagen is a DNA vaccine comprising a plasmid that contains SQSTM1, which encodes for p62, resulting in the prevention of tumor growth and enhancement of chemotherapeutic sensitivity (PMID: 28881846).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Elenagen||Phase Ib/II||Actionable||In a Phase I/IIa trial, Elenagen treatment resulted in a best response of stable disease in 44% (12/27) of patients with advanced solid tumors (PMID: 28881846).||28881846|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|